References
- 1. Marton I, Agócs S, Babik B. Az anaemiák epidemiológiája. [Epidemiology of anemia]. Orv Hetil. 2020;161(37):1569-73. DOI: 10.1556/650.2020.3191610.1556/650.2020.3191632894736
- 2. FAO, WHO. World Declaration and Plan of Action for Nutrition. International Conference on Nutrition. Rome, Food and Agriculture Organization of the United Nations, December 1992.
- 3. McLean E, Cogswell M, Egli I, de Benoist B. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. Geneva, Switzerland World Health Organization. 2008.
- 4. Kassebaum NJ, Jasrasaria R, Naghavi M, Wuklf SK, Johns N, Lozano R et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 1990;123(5):615-24. DOI: 10.1182/blood-2013-06-50832510.1182/blood-2013-06-508325390775024297872
- 5. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161(5):639-48. DOI: 10.1111/bjh.1231110.1111/bjh.1231123573815
- 6. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Niniraki M, Kouroumalis EA. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Ann Gastroenterol. 2011;24(2):108-14.
- 7. Tijanić I, Vučić M, Golubovic LM. The significance of soluble transferrin receptors in diagnosing iron deficiency anemia. Rev Romana Med Lab. 2015;23(3):275-83. DOI: 10.1515/rrlm-2015-003010.1515/rrlm-2015-0030
- 8. Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets. 2019;23(5):407-21. DOI: 10.1080/14728222.2019.159935810.1080/14728222.2019.159935830907175
- 9. Nakanishi T, Kimura T, Kuragano T. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease. Contrib Nephrol 2019;198:124-34. DOI: 10.1159/00049663610.1159/00049663630991414
- 10. Miseta A, Nagy J, Nagy T, Poór VS, Fekete Zs, Sipos K. Hepcidin and its potential clinical utility. Cell Biol Int. 2015;39(11):1191-202. DOI: 10.1002/cbin.1050510.1002/cbin.1050526109250
- 11. Van Den Bossche J, Devreese K, Malfait R, Van de Vyvere M, Wauters A, Neeis H, et al. Reference Intervals for a Complete Blood Count Determined on different Automated Haematology Analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120. 2002;40(1):69-73. DOI: 10.1515/CCLM.2002.01410.1515/CCLM.2002.01411916274
- 12. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23. DOI: 10.1056/NEJMra04180910.1056/NEJMra04180915758012
- 13. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832-43. DOI: 10.1056/NEJMra140103810.1056/NEJMra140103825946282
- 14. Hempel E V., Bollard ER. The Evidence-Based Evaluation of Iron Deficiency Anemia. Med Clin North Am. 2016;100(5):1065-75. DOI: 10.1016/j. mcna.2016.04.015
- 15. Retteghy TA. A vértakarékos betegellátás a perioperatív szakban. [Perioperative Patient Blood Management]. Hematológia−Transzfuziológia. 2018;51(4):194-203. DOI: 10.1556/2068.2018.51.4.410.1556/2068.2018.51.4.4
- 16. Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ, Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS ONE. Public Library of Science; 2015;10(2):e0117383. DOI: 10.1371/journal. pone.0117383
- 17. Kloss-Brandstätter A, Erhart G, Lamina C, Meister B, Haun M, Coassin S, et al. Candidate gene sequencing of SLC11A2 and TMPRSS6 in a family with severe anaemia: common SNPs, rare haplotypes, no causative mutation. PLoS One. 2012;7(4):e35015. DOI: 10.1371/journal.pone.003501510.1371/journal.pone.0035015
- 18. Gasché C, Dejaco C, Waldhoer T, Tillinger W, Rein-isch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease: A randomised, controlled trial. Ann Intern Med. 1997;126(10):782-7. DOI: 10.7326/0003-4819-126-10-199705150-0000610.7326/0003-4819-126-10-199705150-00006
- 19. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-8. DOI: 10.1002/ajh.2420110.1002/ajh.24201
- 20. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. The Lancet, 2007;369(9572):1502-4. DOI: 10.1016/S0140-6736(07)60689-810.1016/S0140-6736(07)60689-8
- 21. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010;60(6 a):362-72. DOI: 10.1055/s-0031-129630110.1055/s-0031-129630120648928
- 22. Mu-oz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia, Expert Opin Drug Saf, 2018; 17(2):149-59. DOI: 10.1080/14740338.2018.140000910.1080/14740338.2018.140000929103332
- 23. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstet. 2008;101(1):67-73. DOI: 10.1016/j.ijgo.2007.10.00910.1016/j.ijgo.2007.10.00918234203
- 24. Coyne DW, Adkinson FN, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003;63(1):217-24. DOI: 10.1046/j.1523-1755.2003.00703.x10.1046/j.1523-1755.2003.00703.x12472786
- 25. Eche IM, Owen KL, Eche IJ, Patel P, Sabe M. Safety and Effectiveness of an Accelerated Intravenous Iron Administration Protocol in Hospitalised Patients With Heart Failure. J Cardiovasc Pharmacol Ther. 2021;26(4):365-70. DOI: 10.1177/107424842198987110.1177/107424842198987133563034
- 26. Hussain I, Bhoyroo J, Butcher A, Koch TA He A, Bregman DB. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013;2013:169107. DOI: 10.1155/2013/16910710.1155/2013/169107
- 27. Khalafallah AA, Yan C, Al-Badri R, Robinson E, Kirk-by BE, Ingram E, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol. 2016;3(9):e415-25. DOI: 10.1016/S2352-3026(16)30078-310.1016/S2352-3026(16)30078-3
- 28. Van Empel VP, Lee J, Williams TJ, Kaye DM. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2014;23(3):287-92. DOI: 10.1016/j.hlc.2013.08.00710.1016/j.hlc.2013.08.007
- 29. Powers JM, Buchanan GR. Diagnosis and Management of Iron Deficiency Anemia. Hematol Oncol Clin North Am. 2014;28(4):729-45. DOI: 10.1016/j. hoc.2014.04.007
- 30. Johnson Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol. 2011;4(3):177-84. DOI: 10.1177/1756283X1139873610.1177/1756283X11398736
- 31. Price EA, Mehra R, Holmes TH, Schrier SL. Anemia in older persons: Etiology and evaluation. Blood Cells Mol Dis. 2011;46(2):159-65. DOI: 10.1016/j. bcmd.2010.11.004
- 32. Baird-Gunning J, Bromley J. Correcting iron deficiency. Aust Prescr. 2016;39(6):193-9. DOI: 10.18773/aust-prescr.2016.069
- 33. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis; 2001;37(1 Suppl 1):182-238. DOI: 10.1016/S0272-6386(01)70008-X10.1016/S0272-6386(01)70008-X
- 34. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;12:CD010590. DOI: 10.1002/14651858. CD010590.pub210.1002/14651858
- 35. Tilea I, Petra DN, Serban RC, Gabor MR, Tilinca MC, Azamfirei L., et al. Short-term impact of iron deficiency in different subsets of patients with precapillary pulmonary hypertension from an Eastern European pulmonary hypertension referral center, Int J Gen Med, 2021;14:3355-66. DOI: 10.2147/IJGM.S31834310.2147/IJGM.S318343828522934285560
- 36. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. CONFIRMHF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-68. DOI: 10.1093/eurheartj/ehu38510.1093/eurheartj/ehu385435935925176939
- 37. A. M. Naidech, M. J. Kahn, W. Soong, Green D, Hunt Batjer H, Bleck TP. Packed Red Blood Cell Transfusion Causes Greater Hemoglobin Rise at a Lower Starting Hemoglobin in Patients with Subarachnoid Hemorrhage, Neurocrit Care, 2008;9(2):198-203. DOI: 10.1007/s12028-008-9113-810.1007/s12028-008-9113-818542851
- 38. Dignass A. Farrag K. Stein J. Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. Int J Chronic Dis. 2018;2018:9394060. DOI: 10.1155/2018/939406010.1155/2018/9394060587889029744352